Technology ID
TAB-2639
Antigen-capture Electrochemiluminescent Assay for Determining Rabies Vaccine Potency
E-Numbers
E-180-2013-0
Co-Inventors
Rupprecht, Charles (CDC)
Applications
Vaccines
Diagnostics
Therapeutic Areas
Infectious Disease
Development Status
- Pre-clinical
- In vitro data available
- In vivo data available (animal)
Lead IC
CDC
ICs
CDC
CDC researchers developed a more efficient method of assessing rabies vaccine potency using an antigen-capture electrochemiluminescent (ECL) assay. This assay utilizes SULFO-NHS-Ester labeled murine monoclonal antibodies to quantify glycoprotein concentration, which is an indicator of vaccine potency. Currently, the potency of rabies vaccines is determined by the effective-dose (ED50) mouse study evaluation method, which is more than 50 years old. The labor-intensive ED50 evaluation method has high operating costs, extensive biosafety requirements, and requires the sacrifice of a large number of animals. CDC researchers have addressed these issues by developing a competitive in vitro antigen-capture assay that is rapid, highly robust, reproducible, flexible and much less expensive to implement than the traditional ED50-mouse study evaluation.
Commercial Applications
- Rabies vaccine design and development
- Vaccine quality control and quality assurance testing
- In vitro assay for rabies virus glycoprotein
Competitive Advantages
- Efficient vaccine evaluation
- Highly robust, reproducible and flexible
- Easily standardized for consistent, universal usage and assurance of batch-to-batch vaccine homogeneity
- In vitro assay may replace the 50 year old ED50 mouse procedure
Licensing Contact: